Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.76 |
| ▸ | CA12 | O43570 | 4/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407414 | 0.87 | KEAP1 (1.00) | KEAP1CA12CA9CA2CA1 | |
| Hydrochloric Acid SCHEMBL3516799 | 0.85 | KEAP1 (0.96) | KEAP1CA12CA9CA2CA1 | |
| SCHEMBL4663044 | 0.82 | KEAP1 (0.76) | KEAP1CA12CA9CA2CA1 | |
| SCHEMBL13895345 | 0.82 | KEAP1 (0.76) | KEAP1CA12CA9CA2CA1 | |
| SCHEMBL4662819 | 0.82 | CA12 (0.87) | KEAP1CA12CA9CA2CA1 | |
| SCHEMBL4662845 | 0.82 | KEAP1 (0.76) | KEAP1CA12CA9CA2CA1 | |
| SCHEMBL5960098 | 0.82 | KEAP1 (0.76) | KEAP1CA12CA9CA2CA1 | |
| SCHEMBL4662824 | 0.81 | KEAP1 (0.69) | KEAP1CA12CA9CA2CA1 | |
| SCHEMBL5165491 | 0.81 | CYP19A1 (0.71) | KEAP1CA12CA9CA2CA1 | |
| SCHEMBL11105032 | 0.79 | KEAP1 (0.71) | KEAP1CA12CA9CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007760-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007108569-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-09-27 | — | — | WO | disclosed |
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | KEAP1 3626/4885CA12 4195/4885CA9 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.